Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade A 173.42 -1.16% -2.03
VRTX closed down 1.16 percent on Thursday, December 13, 2018, on 69 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical VRTX trend table...

Date Alert Name Type % Chg
Dec 13 Fell Below 50 DMA Bearish 0.00%
Dec 13 Cup with Handle Other 0.00%
Dec 12 Crossed Above 50 DMA Bullish -1.16%
Dec 12 Cup with Handle Other -1.16%
Dec 12 NR7 Range Contraction -1.16%
Dec 11 50 DMA Resistance Bearish 0.11%
Dec 11 20 DMA Support Bullish 0.11%
Dec 11 Cup with Handle Other 0.11%
Dec 10 200 DMA Support Bullish -0.21%
Dec 10 20 DMA Support Bullish -0.21%

Older signals for VRTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 194.92
52 Week Low 142.05
Average Volume 1,416,310
200-Day Moving Average 169.1821
50-Day Moving Average 175.0646
20-Day Moving Average 171.479
10-Day Moving Average 177.052
Average True Range 6.2126
ADX 15.3
+DI 23.2267
-DI 26.6752
Chandelier Exit (Long, 3 ATRs ) 169.1222
Chandelier Exit (Short, 3 ATRs ) 175.9228
Upper Bollinger Band 186.6178
Lower Bollinger Band 156.3402
Percent B (%b) 0.56
BandWidth 17.656739
MACD Line 0.5311
MACD Signal Line 0.3123
MACD Histogram 0.2188
Fundamentals Value
Market Cap 43.73 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 166.75
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 182.26
Resistance 3 (R3) 182.63 180.06 180.78
Resistance 2 (R2) 180.06 177.81 179.87 180.29
Resistance 1 (R1) 176.74 176.42 175.46 176.37 179.80
Pivot Point 174.17 174.17 173.53 173.98 174.17
Support 1 (S1) 170.85 171.92 169.57 170.48 167.04
Support 2 (S2) 168.28 170.53 168.09 166.55
Support 3 (S3) 164.96 168.28 166.06
Support 4 (S4) 164.59